Not photodynamic therapyTo state the obvious, if Metaformin can successfully activate Rutherrin to produce ROS and selectively kill cancer cells then Theralase has left the realm of photodynamic therapy and joined the mainstream medical treatment world of needle sticking and pill popping.
This should make at least some of Theralase's ACT more appealing to big pharma. If, in some futute procedure, patients aren't completely cancer free after taking their Rutherrin/Metaformin then doctors can freshen up the effect with a light dose of X-rays which are a pretty mainstream cancer treatment already.
The fact that both drugs can cross the blood-brain barrier might effect the design of the upcoming gbm trial by adding Metaformin to the Rutherrin, X-ray mix.